These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 373944)
1. When and how to stop a clinical trial: introduction. Meinert CL Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):632. PubMed ID: 373944 [No Abstract] [Full Text] [Related]
2. When and how to stop a clinical trial: invited remarks. Hamilton MT Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):647-8. PubMed ID: 373947 [No Abstract] [Full Text] [Related]
3. When and how to stop a clinical trial: invited remarks. Chalmers TC Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):649-50. PubMed ID: 373948 [No Abstract] [Full Text] [Related]
4. When and how to stop a clinical trial: invited remarks. Stamler J Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):651-4. PubMed ID: 373949 [No Abstract] [Full Text] [Related]
5. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Problems of omission in communications. Mosteller F Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):761-4. PubMed ID: 373970 [No Abstract] [Full Text] [Related]
7. A framework for the quality assurance of clinical data. Williams OD Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):700-2. PubMed ID: 373958 [No Abstract] [Full Text] [Related]
9. Problems in publication of clinical trial methodology. Lasagna L Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):751-3. PubMed ID: 373967 [TBL] [Abstract][Full Text] [Related]
10. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Methodology: the case for improved communications. Meinert CL; Hawkins BS Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):754-7. PubMed ID: 373968 [TBL] [Abstract][Full Text] [Related]
12. Who will be effective as a clinical trials investigator and what are adequate incentives? Appendix 1: A proposed mechanism and set of criteria for the evaluation of the scientific contribution of individual investigators in collaborative studies, including large clinical trials. Stamler R Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):671-2. PubMed ID: 373952 [No Abstract] [Full Text] [Related]
13. Before-and-after comparisons: a cautionary role. Christie D Br Med J; 1979 Dec 22-29; 2(6205):1629-30. PubMed ID: 534920 [No Abstract] [Full Text] [Related]
15. Is there a hierarchy of methods in clinical research? Vandenbroucke JP Klin Wochenschr; 1989 May; 67(10):515-7. PubMed ID: 2661911 [No Abstract] [Full Text] [Related]
16. Patient recruitment: other examples of recruitment problems and solutions. Prout TE Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):695-6. PubMed ID: 373957 [TBL] [Abstract][Full Text] [Related]
17. Postmarketing studies of drug efficacy. Strom BL; Melmon KL; Miettinen OS Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034 [No Abstract] [Full Text] [Related]